News

Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.

Hovnanians discusses the benefits of oral versus injectable PCSK9s, as well as the ongoing research to clear enlicitide alone for cardiovascular indications.

Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

Aaron Waxman, MD, PhD, discusses sotatercept’s new indication and recommendation in patients newly diagnosed with PAH at intermediate to high risk.

Iltefat H. Hamzavi, MD, explains why vitiligo responds slowly, why stabilization matters, and what Tranquillo data mean for future treatment.

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

On World Oxygen Day, the COPD Foundation's Mike Hess outlines the stigma, training gaps, and Medicare barriers affecting patients on supplemental oxygen.

Drinking fell for the first time since COVID-19, but not for adults 50 to 64. Hepatologists explain what clinicians can do to close the gap.

From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.

Stay up-to-date with the latest in FDA decisions, trial readouts, and key clinician insights from all corners of endocrinology.

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.

The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.